These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 30543573

  • 1. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 2. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.
    Scand J Gastroenterol; 2015 Feb; 50(9):1110-7. PubMed ID: 25865965
    [Abstract] [Full Text] [Related]

  • 3. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY, Kang B, Choe YH.
    Gut Liver; 2019 Sep 15; 13(5):541-548. PubMed ID: 30970435
    [Abstract] [Full Text] [Related]

  • 4. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L, Kolho KL.
    J Pediatr Gastroenterol Nutr; 2017 Feb 15; 64(2):272-278. PubMed ID: 27149256
    [Abstract] [Full Text] [Related]

  • 5. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Pediatr Gastroenterol Nutr; 2019 Jun 15; 68(6):847-853. PubMed ID: 30633108
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
    Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S, Cheifetz A, Fabien N, Barrau M, Paul S.
    J Crohns Colitis; 2024 May 31; 18(5):679-685. PubMed ID: 37934041
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S.
    J Crohns Colitis; 2018 Nov 15; 12(11):1316-1325. PubMed ID: 30239644
    [Abstract] [Full Text] [Related]

  • 13. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF.
    Eur J Clin Pharmacol; 2021 Jan 15; 77(1):55-62. PubMed ID: 32803288
    [Abstract] [Full Text] [Related]

  • 14. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S.
    J Pediatr Gastroenterol Nutr; 2019 Jan 15; 68(1):37-44. PubMed ID: 30211845
    [Abstract] [Full Text] [Related]

  • 15. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
    Nemoz B, Ternant D, Bailly S, Gautier-Veyret E, Jourdil JF, Bonaz B, Stanke-Labesque F.
    Br J Clin Pharmacol; 2019 Apr 15; 85(4):722-728. PubMed ID: 30575085
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.